Docebo Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-69.0% vs price
Base Case (Median)
-57.3% vs price
Bull Case (75th pct.)
17.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-6.40 | -128.2% | High (40%) |
| PE Comparable | $29.49 | 30.0% | Medium (25%) |
| Growth Trajectory DCF | $62.68 | 176.2% | Medium (20%) |
| Graham Number | $8.20 | -63.9% | Low (10%) |
| EV/EBITDA | $9.68 | -57.3% | Medium (20%) |
| EV/FCF | $23.98 | 5.7% | Medium (20%) |
| Earnings Power Value | $5.85 | -74.2% | Medium (50%) |
Based on 7 out of 8 methods, DCBO appears fairly valued at the current price of $22.69. The base case fair value of $9.68 implies 57.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.